Acute radiation syndrome

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

Retrieved on: 
Thursday, March 28, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Radiation, Acute radiation syndrome, Attack, ARS, Inflammation, Education, Chronic obstructive pulmonary disease, RNCP, USUHS, Virus, IND, European Medicines Agency, Outline of health sciences, Nausea, Accident, Hypoxia (medical), NIAID, Defense Threat Reduction Agency, AFRRI, HIE, Vaccine, Collection, Vomiting, Food, FDA, Defense, Infection, Peptide, Pharmaceutical industry

“We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.

Key Points: 
  • “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
  • AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
  • It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
  • ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.

NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

Retrieved on: 
Tuesday, April 2, 2024
Mallinckrodt, Inflammation, Pharmacology, McGill University, Organization, Acute radiation syndrome, ARS, KOSDAQ, Research, EDT, Senior, Doctor of Philosophy, IL-7, Human Genome Sciences, Drug development, Division, NIT, Vertex Pharmaceuticals

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).

Key Points: 
  • ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).
  • Se Hwan Yang, Ph.D., as Chief Executive Officer of NeoImmuneTech, Inc.
  • In his new role, Dr. Oh will lead NeoImmuneTech from its Rockville headquarters and overview all the operations in Korea.
  • Se Hwan Yang initiated, aligning the company on our business priorities, and stepping up this new phase of NeoImmuneTech."

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Retrieved on: 
Tuesday, March 5, 2024
Infection, MCM, NIAID, NIH, ARS, TEL, FDA, SPHK2, Food, Acute radiation syndrome, RNCP, Bronchiolitis obliterans, Radiation, Mustard gas, HHS, Administration, COVID-19, Chem, ASPR, CCRP, Fibrosis, Acute respiratory distress syndrome, Development, White lung, Opaganib, Pharmaceutical industry

The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.

Key Points: 
  • The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.
  • "With the alarming increase in global geo-political instability, the opportunity to evaluate opaganib as a potential vital protective agent against chemical attack is inspiring.
  • "Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure.
  • Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute for use against potential chemical weapon attack, if approved by the FDA.

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Retrieved on: 
Tuesday, February 20, 2024
Bangladesh Technical Education Board, Research, Fibrosis, Molecule, ARS, NIH, Inflammation, IL-6, FDA, TEL, Food, Acute radiation syndrome, RNCP, Radiation, Mustard gas, COVID-19, Canadian International Council, Survival, Opaganib, Medical imaging

The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradiation and in cancer radiotherapy.

Key Points: 
  • The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradiation and in cancer radiotherapy.
  • Radiation-induced inflammation is known to occur in two phases – in an initial inflammatory response immediately after irradiation and in a delayed response that can occur weeks later.
  • Thus, treating with opaganib during both initial and delayed phases of inflammation provided the greatest improvement in survival.
  • "These data further demonstrate that sphingolipid metabolism is a critical regulator of fibrogenesis, and specifically show that opaganib suppresses radiation-induced pulmonary inflammation and fibrosis."

NeoImmuneTech Welcomes a New President for its Development and Business

Retrieved on: 
Monday, January 15, 2024
Senior, Research, Human Genome Sciences, Biosimilar, NIT, Pharmacology, McGill University, Division, Drug development, Inflammation, Acute radiation syndrome, Organization, Doctor of Philosophy, IL-7, ARS, Mallinckrodt, Vertex Pharmaceuticals, Pharmaceutical industry

ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.

Key Points: 
  • ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.
  • Dr. Oh is an expert in regulatory policies and drug development, encompassing both biologics and small molecules.
  • Se Hwan Yang, Ph.D., Chief Executive Officer of NeoImmuneTech, Inc. said: "We are delighted to welcome Dr. Oh to our team.
  • His strong expertise and extensive network are invaluable assets that will propel our clinical development program and business activities.

FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome

Retrieved on: 
Monday, November 20, 2023
Medicine, NIAID, Research, Safety, Immune system, Food, ARS, NIT, Hope, ODD, Radiation exposure, FDA, Acute radiation syndrome, NIH, Orphan drug, Bangladesh Technical Education Board, Bone marrow, Infection, Pharmaceutical industry

The FDA's Orphan Drug Designation is aimed at advancing treatments for rare diseases, including Acute Radiation Syndrome (ARS), which currently has limited treatment options.

Key Points: 
  • The FDA's Orphan Drug Designation is aimed at advancing treatments for rare diseases, including Acute Radiation Syndrome (ARS), which currently has limited treatment options.
  • NeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS.
  • ROCKVILLE, Md, Nov. 20, 2023 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for their investigational drug NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of Acute Radiation Syndrome (ARS).
  • ARS is an illness that occurs following a high dose of radiation exposure, leading to severe damage to the bone marrow and the immune system.

Senator Mark Warner Visits ReAlta Life Sciences’ Biotech Research Facility, Highlights Importance of Rare Disease Innovation

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, White House, Federal Government, Health, Healthcare Reform, Pharmaceutical, Other Policy Issues, Other Science, Research, Public Policy, Government, Science, Clinical Trials, Multimedia, Chief Management Officer of the Department of Defense, Doctor of Philosophy, CSO, Asphyxia, COVID, Sepsis, MD, Graft-versus-host disease, Warner, United States Senate Select Committee on Nutrition and Human Needs, HIE, CMO, Hypoxia (medical), Rodels-Realta railway station, Immune system, Military personnel, Senator Warner, Acute radiation syndrome, BARDA, Patient, United States Senate Select Committee on Intelligence, Pharmaceutical industry, Intelligence

ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the power of the immune system to address life-threatening diseases, was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the power of the immune system to address life-threatening diseases, was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231012073021/en/
    Sen. Mark Warner (D-Va) with ReAlta CEO Dr. Ulrich Thienel, board chairman Edward Heidt, Jr., CMO Dr. Kenji Cunnion, CSO Dr. Neel Krishna, and ReAlta staff.
  • “ReAlta is on the cutting edge of research in a variety of fronts – from COVID to birth asphyxia,” said Sen. Mark R. Warner.
  • The company looks forward to continuing to push the boundaries of what is possible in the fight against life-threatening rare diseases.

Humanetics Corporation Awarded Contract From Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury

Retrieved on: 
Wednesday, September 6, 2023
Defense, Other Science, Radiology, White House, Federal Government, Pharmaceutical, Research, Other Defense, Oncology, Contracts, Homeland Security, Science, Clinical Trials, Public Policy, Government, FDA, Biotechnology, Health, Law Enforcement, Emergency Services, COVID-19, Military, BIO, Radiation, Acute radiation syndrome, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, ARS, United States Department of Defense, OTA, Policy, Clinical trial, Cancer, Lung cancer, Food and Drug Administration, Terrorism, Bangladesh Technical Education Board, DOD, JPM, Humanetics, Patient, Joint Program Executive Office Chemical and Biological Defense, Chronic radiation syndrome, Conventional weapon, Radiation exposure, Food, Pharmaceutical industry, Vaccine, Chemical substance

Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.

Key Points: 
  • Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.
  • In addition, the OTA agreement provides options for the DOD to fund all activities required to bring BIO 300 to full FDA approval.
  • Exposure to radiation from accidental or intentional sources can lead to acute radiation syndrome (ARS), which consists of numerous serious and life-threatening injuries.
  • The JPEO-CBRND will manage the OTA agreement, overseeing the development of BIO 300, exclusively licensed to Humanetics for advanced development and FDA licensing.

Ceramedix Awarded Phase 2B NIH SBIR Grant to Evaluate the Non-Clinical Pharmacology of Its Lead Candidate to Support IND Submission

Retrieved on: 
Thursday, August 24, 2023
Acute radiation syndrome, U.S. Department of Defense Strategy for Operating in Cyberspace, ARS, Human services, SBIR, National Institute of Allergy and Infectious Diseases, Office of Inspector General, U.S. Department of Health and Human Services, Infection, Bangladesh Technical Education Board, National Institutes of Health, Small Business Innovation Research, NIAID, FDA, Pharmacology, IND, NIH, Radiation exposure, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, III, Pharmaceutical industry

NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Ceramedix Holding, LLC (Ceramedix), a privately-held biotherapeutics company developing a new class of antibody-based drugs designed with the aim to address novel disease targets involving the microvasculature, today announced it was awarded a $3,007,043 Phase 2B National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant to evaluate the non-clinical pharmacology of its lead drug candidate. Specifically, the anti-ceramide antibody that disrupts cell death signaling is in development through the NIH as a potential therapeutic to mitigate and/or treat illness due to radiation exposure. The grant was issued by the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH, a part of the U.S. Department of Health and Human Services.

Key Points: 
  • Specifically, the anti-ceramide antibody that disrupts cell death signaling is in development through the NIH as a potential therapeutic to mitigate and/or treat illness due to radiation exposure.
  • The grant was issued by the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH, a part of the U.S. Department of Health and Human Services.
  • The grant will specifically fund the establishment of independent potency assay capabilities within Ceramedix, as well as in vitro studies to better understand the pharmacology of the antibody.
  • "The award of this NIH SBIR grant reflects potential of the antibody to prevent and treat lethal gastrointestinal (GI) acute radiation syndrome (ARS)," stated Charles L. Dimmler, III, Managing Member of Ceramedix.

BIO 300 Featured at the 2023 Military Health System Research Symposium

Retrieved on: 
Tuesday, August 22, 2023
Biotechnology, Health, General Health, Pharmaceutical, Veterans, Infectious Diseases, Military, Other Defense, Defense, COVID-19, Clinical Trials, BIO, Radiation, Acute radiation syndrome, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, ARS, Policy, Uniformed Services University of the Health Sciences, Armed Forces Radiobiology Research Institute, United States Department of the Army, Research, Government, Military personnel, DOD, Federal government of the United States, Humanetics, Patient, Data, Outline of health sciences, Privacy and the US government, FDA, Department of Defence, Vaccine, School of Advanced Warfighting

Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2023 Military Health System Research Symposium (MHSRS), held August 14-17th.

Key Points: 
  • Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2023 Military Health System Research Symposium (MHSRS), held August 14-17th.
  • BIO 300 is being developed for use by military personnel, first responders, and at-risk civilian populations to prevent the harmful and deadly effects of ARS.
  • There is an urgent need for drugs like BIO 300, as no FDA-approved countermeasures provide prophylactic protection against ARS.
  • Professor Singh’s presentation highlighted the research on BIO 300 that has positioned it as the most advanced prophylactic medical countermeasures currently under development for ARS.